anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Chronic kidney disease (CKD) is a major health problem with an increasing epidemiological burden, and is the 16th leading cause of years of life lost worldwide. It is estimated that more than 10% of the population have a variable stage of CKD, while about 850 million people worldwide are affected. Nevertheless, public awareness remains low, clinical access is inappropriate in many circumstances and medication is still ineffective due to the lack of clear therapeutic targets. One of the main issues that drives these problems is the fact that CKD remains a clinical entity with significant causal ambiguity. Beyond diabetes mellitus and hypertension, which are the two major causes of kidney disease, there are still many gray areas in the diagnostic context of CKD. Genetics nowadays emerges as a promising field in nephrology. The role of genetic factors in CKD's causes and predisposition is well documented and thousands of genetic variants are well established to contribute to the high burden of disease. Next-generation sequencing is increasingly revealing old and new rare variants that cause Mendelian forms of chronic nephropathy while genome-wide association studies (GWAS) uncover common variants associated with CKD-defining traits in the general population. In this article we review how GWAS has revolutionized-and continues to revolutionize-the old concept of CKD. Furthermore, we present how the investigation of common genetic variants with previously unknown kidney significance has begun to expand our knowledge on disease understanding, providing valuable insights into disease mechanisms and perhaps paving the way for novel therapeutic targets.
Patients who are in stage II-III with sarcoidosis diagnosed pulmonary involvement who are admitted to the Department of Chest Diseases of Cerrahpaşa Medical Faculty Hospital of Istanbul University will be included in the 30-70 age group 6 months after systemic treatment or no treatment. Patients with stages I and IV, malignancy, heart failure, orthopedic problems and who have to undergo systemic sarcoidosis treatment during the study will not be included in the study. Thirty-four patients who meet the inclusion criteria will be included in the study by signing the informed consent form. In the first evaluation, demographic information and clinical characteristics of the patients will be noted. Lower and upper extremity functional capacities of the patients before and after training will be evaluated with 6-minute walk test (6MWT), 6-minute step test (6DST), 6-minute pegboard ring test (6DPBRT) and 30-second sit-down test. Percentage values of FVC, FEV1, FEV1 / FVC, PEF, FEF (25-75%) parameters according to measured and expected values will be recorded by performing pulmonary function test. Respiratory muscle strength will be determined by measuring maximal inspiratory pressure (MRP) and maximal expiratory pressure (MEP) with the intraoral pressure gauge. Dyspnea sensation Modified Borg and Modified Medical Research Council (MMRC) scale, fatigue state Fatigue Severity Scale (FSS), peripheral muscle strength hand dynamometer, quality of life George Respiratory Diseases Questionnaire (SGRQ), anxiety and depression status Hospital Anxiety and Depression Scale (HAD), physical activity level International Physical Activity Questionnaire-Short form (IPAQ-S), cognitive function Montreal Cognitive Assessment Scale (MOCA), daily living activities London Chest Daily Living Activities Scale and sleep quality will be evaluated with Epworth Sleepiness Scale (ESS).
PURPOSE:To provide the titled adjuvant capable of promoting the absorption of the orally administered active drug component such as beta-lactam antibiotic substance, etc., by using the triterpenoid saponin obtained by extracting the shell of MUKUROJI (Sapindus mukurossi Gaerth.) with a lower aliphatic alcohol, etc., as an active component. CONSTITUTION:The shell of MUKUROJI is optionally defatted, and extracted with a lower aliphatic alcohol (e.g. ethanol) or a mixture of water and a lower aliphatic alcohol. The extracted fraction is subjected to silica gel column chromatography to separate the triterpenoid saponin of formulaI[R is group of formula II (saponin A), formula III (saponin B) or formula IV (saponin C)]. The objective drug can be prepared by using these saponins as active components.
The treatment landscape for BCR/ABL-negative myeloproliferative neoplasms (MPNs), driven by JAK2, CALR, and MPL mutations, has evolved significantly over the last decade. Recent regulatory approvals in polycythemia vera (PV) include the JAK inhibitor ruxolitinib, and more recently, a novel recombinant interferon alfa-2 (IFN-α) therapeutic agent. Many clinical trials have documented the safety and efficacy of IFN-α therapy in PV and essential thrombocythemia, the classical BCR/ABL-negative MPNs. Used off-label for more than 30 years as a cytoreductive agent, IFN-α therapy promotes significant clinical, hematologic, and molecular responses. In some IFN-α-treated patients, partial or complete reduction of the mutant JAK2 allele burden may lead to a durable measurable residual disease state, owing to the ability of long-term IFN-α therapy to selectively deplete mutant JAK2-harboring hematopoietic stem cells. Pegylated IFN-α forms were developed to improve the drug stability and tolerability of first-generation IFN-α therapeutics. More recently, a novel pegylated IFN-α, ropeginterferon alfa-2b, received approval for PV by the European Medicines Agency and the US Food and Drug Administration in 2019 and 2021, respectively. This article reviews the clinical research and recent advances that led to the first regulatory approval of IFN-α in a BCR/ABL-negative MPN and its future promise as a disease-modifying therapeutic agent.
FIELD: pharmacy, medicinal preparations from plant raw. SUBSTANCE: method involves an aqueous extraction of plant raw and extract filtering. New in method: plant raw is taken at the following ratio: common immortelle flowers : peppermint leaves : pot-marigold flowers : dandelion roots : rose fruits : wild strawberry leaves : licorice roots : elecampane roots : march trifoil leaves = 2:1:2:1:3:3:1:2:1, respectively. After extraction and filtration extract is mixed with mineral water "Essentuki N 4". Prepared extract shows curative properties with regard to gallbladder diseases. EFFECT: enhanced curative properties of preparation, improved composition of plant components enhancing gallbladder tonicity.
The thick blood infusion and the preparation method belong to the traditional Chinese medicine domain. Thick blood (high blood viscosity, high blood fats) has been threatening the healthy of people for a long time, frequently leading to the occurrence of own disease due to the incurability. At present there is no medicine that can permanently cure the thick blood and arteriosclerosis thoroughly. What can people do is from each related factor. Once the disease attacks, the development trend is difficult to stop. The present invention comprises: traditional Chinese medicine: the weight share ratio of codonopsis pilosula 15. The traditional Chinese medicine also comprises: The salvia miltiorrhiza 30, the elevated gastrodia 20, the pinellia 15, the frankincense 15, the rhizoma corydalis 15, Commiphora myrrha 15, the Chinese angelica 15, the earthworm 15, the Chinese hawthorn 15, the sealwort 15, 3710, first Ukraine 15, the Kudzu root 10, the safflower 15, the dried orange peel 20, the tortoise shell 20, the bupleurum chinensis 20, the cuscuth japonica 15, the asparagus 20, the dwarf lilyturf 20. All the above are the weight share ratio. The present invention is used to treat the thick blood and the related symptom of thick blood.
Participants have never received Influenza virus vaccine in the past. They will receive a single dose of Fluzone vaccine on Day 0 and Day 28, respectively.
The invention discloses a traditional Chinese medicine used for treating ulcerative colitis, and a preparation method and a detection method thereof. The traditional Chinese medicine comprises, by weight, 110 to 130 portions of indigo naturalis, 80 to 100 portions of radix codonopsis, 8 0to 100 portions of fried rhizoma atractylodis macrocephalae, 50 to 70 portions of fructus schisandrae chinensis, 50 to 70 portions of cortex fraxini, 50 to 70 portions of marinated fructus mume, 50 to 70 portions of Ivory powder, 50 to 70 portions of pearl powder, 25 to 35 portions of carbonized uroctea compactilis koch, and 10 to 20 portions of human nail. According to the detection method, the contents of indigo blue and indirubin are determined via high performance liquid chromatography. Compatibility of the ingredients is realized. The traditional Chinese medicine is capable of tonifying spleen and clearing damp, astringing and promoting muscle growth, and detoxifying and removing rotten muscle, and can be used for treating ulcerative colitis. Symptoms of ulcerative colitis comprise diarrhea, pus and blood stool, stomachache and tenesmus.
PURPOSE: To obtain an enteric coated preparation coated by a fine powdery enteric coating agent while sprinkling waxes of a liquid state to a solid medicine. CONSTITUTION: This enteric coated preparation is obtained by coating a granular preparation, a powdery preparation or a bulk medicine with a fine powdery enteric coating agent having <=10μm particle diameter (e.g. hydroxypropyl methyl cellulose acetate succinate) while sprinkling waxes of a liquid state at a room temperature or waxes which have <=90 deg.C melting point and are made to be a liquid state by heating and melting (e.g. lauryl alcohol). By the solventless coating not requiring the drying and completed in a short period, the enteric coated preparation having an acid resistance is obtained. Since the drying of solvent is not necessary and the coating time is short, it is possible to shorten the manufacturing process and by the solventless coating, it is possible to apply it to medicines unstable to water and organic solvents.  Further, a surfactant, etc., commonly used in an aqueous enteric coating as a dispersing agent, are not necessary.
The treatment group will receive avapritinib orally. The dosage is 100mg to 300mg qd, allowed to combine with other chemotheray drugs.
Patients in Arm A will receive capecitabine at the oral dose of 1500 mg/mq/die bid from day 1 to day 14 every 28 days plus temozolomide 150 mg/mq/die bid starting on day 10 to 14 every 28 days. Treatment will continue for up to 6 cycles or up to disease progression, unacceptable toxicity or informed consent withdrawal.
A method is disclosed for using fructose-1,6-diphosphate (FDP) to reduce and prevent two very serious problems caused by surgery that requires cardiopulmonary bypass. Before bypass begins, a liquid that contains FDP is intravenously injected into the patient, preferably over a period such as about 10 to 30 minutes, to allow the FDP to permeate in significant quantity into the heart and lungs while the heart is still beating. FDP can be added to the cardioplegia solution that is pumped through the heart to stop the heartbeat, and/or during bypass. This treatment was found to reduce two very important and serious problems that have unavoidably plagued CPB surgery in the past, which are: (1) elevated levels of pulmonary vascular resistance (PVR), which includes pulmonary hypertension; and (2) high occurrence rates for atrial fibrillation. Prior to this discovery, there has never been any satisfactory treatment which could reduce the severity and occurrence rates for these two major problems. FDP also can be co-administered in this manner, along with (1) a buffering or alkalizing agent that counteracts acidosis, such as sodium bicarbonate or THAM, and/or (2) a drug that reduces the formation of lactic acid, such as dichloroacetate.
Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days, beginning one day prior to surgery, continuing on the day of surgery, and for 14 days following surgery. An additional drop was administered between 30-120 minutes prior to surgery.
Invariant Natural Killer T (iNKT) cells are unconventional T cells that respond to microbe-derived glycolipid antigens. iNKT cells exert fast innate effector functions that regulate immune responses in a variety of contexts, including during infection, cancer, or inflammation. The roles these unconventional T cells play in intestinal inflammation remain poorly defined and vary based on the disease model and species. Our previous work suggested that the gut microbiota influenced iNKT cell functions during dextran sulfate sodium-induced colitis in mice. This study, shows that iNKT cell homeostasis and response following activation are altered in germ-free mice. Using prenatal fecal transplant in specific pathogen-free mice, we show that the transcriptional signatures of iNKT cells at steady state and following αGC-mediated activation in vivo are modulated by the microbiota. Our data suggest that iNKT cells sense the microbiota at homeostasis independently of their T cell receptors. Finally, iNKT cell transcriptional signatures are different in male and female mice. Collectively, our findings suggest that sex and the intestinal microbiota are important factors that regulate iNKT cell homeostasis and responses. A deeper understanding of microbiota-iNKT cell interactions and the impact of sex could improve the development of iNKT cell-based immunotherapies.
Lymphatic malformations (LMs) arise from abnormal development of lymphatic vasculature. Primary lymphedema is considered a form of LM. Recently, results in the investigators' laboratory demonstrated that propranolol, a pan beta-adrenergic receptor (βAR) antagonist, had cytotoxic and anti-proliferative effects against cells isolated from LM tissues. Preliminary results from treating symptomatic LM patients with propranolol at a dose range from 0.7-1mg/kg/day demonstrated a 70% positive response rate, with patients reporting improvement in their symptoms.

Propranolol has been used for different indications for many years. Propranolol is accepted for use in infants with hemangiomas and supraventricular tachycardia. Hemangeol was approved by the FDA for use in infants with hemangiomas. However, βAR antagonists are not without potential adverse effects, including hypotension, bradycardia, hypoglycemia, bronchospasms, and sleep disturbances. FDA-approved dose range for treating hemangiomas in infants (\>5 weeks old, \>2kg) ranged from 1-3mg/kg/day in divided doses. Propranolol doses of up to 4mg/kg/day has been used for pediatric supraventricular tachycardia. Therefore, the investigator's experience with propranolol use in LM patients have been at the low end of most accepted clinical indications. The investigators propose to escalate propranolol dosages up to 3mg/kg/day in this study, well below the dose ranges currently used in clinical settings.

This dose range of 0.7-1mg/kg/day was chosen for LM patients as it was the low end of dose range for infants treated with propranolol for problematic hemangiomas, a related vascular anomaly. At this dose, no significant hemodynamic adverse effects were noted in LM patients. However, when patients stopped propranolol or their dose fell below 0.7mg/kg/day, they suffered rebound worsening of their symptoms. Moreover, inflammatory events such as infections temporarily overcame the effects of 0.7-1mg/kg/day of propranolol. Thus, it is unknown whether maximum propranolol efficacy was achieved at the current dose range. The investigators propose to examine whether optimized propranolol usage for treatment of LM patients has been achieved. The primary endpoint for this study is to ascertain whether LM patients can tolerate higher doses of propranolol, as measured by known propranolol adverse effects and patient-reported symptoms. A secondary endpoint will address whether patient-reported LM symptoms and quality of life are improved with higher doses of propranolol; objective findings such as LM size on physical examination and imaging studies will be analyzed as well. In addition, LM tissue biopsies will acquired from patients before and after propranolol treatment for further analyses of disease progression.
Adenosine kinase deficiency (OMIM #614300) is a type of inborn errors of metabolism with multiorgan symptoms primarily neurological disorders, hepatic impairment, global developmental delay, and mild dysmorphism. The genetic causes of adenosine kinase deficiency are homozygous or compound heterozygous loss-of-function variants of ADK. To date, fewer than 25 cases of adenosine kinase deficiency have been reported worldwide and none have been reported in China. In this research, trio whole-exome sequencing (Trio-WES) identified a novel homozygous ADK (NM_001123.4) out-of-frame deletion, c.518_519delCA (p.Thr173Serfs*15), in a Chinese patient with rare phenotypes of sepsis, metabolites disruption and neutrophil dysfunction. This variant was dysfunctional, with marked reduction of ADK level in both the patient's peripheral blood and cells transfected with the corresponding variant. Additionally, metabolomics detected by high-throughput mass spectrometry showed disturbances in the methionine (Met) and energy pathway. RNA sequencing (RNA-seq) of the patient's peripheral blood suggested a defective anti-inflammatory response characterized by impaired neutrophil activation, migration, and degranulation, which might be the primary cause for the sepsis. To our knowledge, we identified the first Chinese patient of adenosine kinase deficiency with a novel homozygous out-of-frame deletion in ADK causing multiorgan disorders, metabolites disruption, rare phenotypes of sepsis, and neutrophil dysfunction. Our findings broaden the genetic spectrum and pathogenic mechanisms of adenosine kinase deficiency.
In patients with chronic obstructive pulmonary disease (COPD) dynamic hyperinflation (DH) and the concurrent mechanical constraints on tidal volume expansion during exercise increase work of breathing and perceived respiratory discomfort, limiting endurance. An additional consequence of DH and the concomitant high mean intrathoracic pressure swings, cardiac performance and, hence, supply of oxygenated blood to the malfunctioning peripheral muscles is further compromised. This contributes to perceived leg discomfort and exercise intolerance.

Bronchodilator therapy is associated with a reduction in operating lung volumes, leading to improvements in perceived breathlessness and exercise tolerance. Heliox (helium and oxygen) is less dense and generates less airway resistance than air. Heliox breathing has been shown to improve exercise tolerance in COPD. A recent study demonstrated that compared to room air, breathing heliox during constant-load exercise (CLE) (continuous) increased inspiratory capacity (IC), and lessened DH, breathlessness and leg discomfort at isotime and at the point of exercise limitation. In addition, heliox breathing increased stroke volume, cardiac output and hence locomotor muscle oxygen delivery. However, the main drawback of heliox supplementation is the high cost, especially when it is used for long periods of time. Previous studies using inspiratory pressure support have shown improvements in dyspnoea and exercise capacity by reducing the work of breathing, as well as improved central hemodynamic responses and peripheral muscle oxygenation.

In comparison to traditional noninvasive ventilators, the Vitabreath device, which provides positive inspiratory pressure, is compact, light and inexpensive. Ease of operation, portability and battery life support use to aid relief of breathlessness, including away from the patient's home. This should facilitate maintenance of, and improvement in, activity. Vitabreath may also prove to be a useful tool to increasing exercise tolerance and the intensity of training, and hence the magnitude of physiological adaptations by mitigating DH during rehabilitative exercise training.
Ursodiol is a bile acid available as 300 mg capsules suitable for oral administration.

  


Ursodiol, USP (ursodeoxycholic acid) is a naturally occurring bile acid found in small quantities in normal human bile and in the biles of certain other mammals. Ursodiol, USP (ursodeoxycholic acid) is a white or almost white crystalline powder, practically insoluble in water, freely soluble in ethanol (96%), slightly soluble in acetone and practically insoluble in methylene chloride. The chemical name for ursodiol is 3α,7β-Dihydroxy-5β-cholan-24-oic acid (C24H40O4). Ursodiol, USP has a molecular weight of 392.6 g/mol. Its structure is shown below:  


  


Inactive Ingredients: Colloidal silicon dioxide, corn starch, and magnesium stearate. Gelatin capsules contain gelatin, iron oxide red, and titanium dioxide. The capsules are printed with edible ink containing black iron oxide, potassium hydroxide, propylene glycol, and shellac.
FIELD: biotechnology, molecular biology, veterinary science. SUBSTANCE: invention relates to DNA fragment encoding an immunogenic surface polypeptide of merosoites Eimeria tenella (molecular mass is 33 kDa). During expression of this fragment in microorganism cells the indicated immunogenic polypeptide is formed. DNA fragment encoding polypeptide is introduced into suitable vector, microorganism cells are transformed with this vector and the end recombinant DNA is isolated from cells where polypeptide expression is occurred. The end polypeptide is isolated from cultural medium. DNA fragment encoding this polypeptide is cloned in a suitable vector, introduced into plasmid containing TK gene of vaccine virus for recombination. Cultured cells are transformed with obtained recombination plasmid temperature-sensitive vaccine virus and vaccine virus of wild type. Transformed cells are cultured at increased temperature, TK-negative vaccine virus is isolated, used its for infection of cultured cells and the end recombinant vaccine virus is selected by the presence of gene of merosoites. Vaccine has recombinant vaccine virus containing DNA fragment or immunogenic surface polypeptide of merosoites and physiologically acceptable carrier. Invention ensures to obtain important vaccine antigens that are essential in protection of domestic poultry and other live organisms against coccidiosis. EFFECT: improved method of preparing polypeptide, plasmid DNA, vaccine virus, microorganism and vaccine. 10 cl, 1 tbl, 15 dwg, 3 ex
Initiative in the Acupressure Group Informed consent form will be signed by the patients who will be included in this group as a result of randomization, and a personal information form and STAI will be filled. Acupressure will be applied 10 minutes before catheter extraction after CAG. Catheter extraction takes approximately 15-20 minutes. VAS will be applied during the catheter extraction process, and then VAS, SAI and PCS will be applied to all patients. Vital signs of patients will be recorded before, during and after catheter extraction.
An evaluation of the incidence of complications resulting from far lateral spine surgery utilizing the K2M RAVINE® Lateral Access System (RAVINE) with ALEUTIAN® Lateral Interbody Spacer System versus literature reported results for the NuVasive XLIF® system (XLIF) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis at L2-S1 requiring surgical intervention at one or two contiguous levels. Safety will be assessed by the following: 1.) Evaluation of all adverse events including device related, procedure related and additional serious adverse events; 2.) Additional surgical intervention at the operative site including the need for removals, revisions, re-operations or supplemental fixation required to modify the device; and 3.) The incidence and severity of any psoas muscle injury, genital femoral nerve injury and lumbar plexus injury will be determined for all patients. Supplemental fixation of any kind may be included as long as the procedure is completed via a minimally invasive approach.